跳至主要内容
临床试验/NCT03040206
NCT03040206已完成不适用

Multicenter Study to Assess the Prognostic Significances of NCCN-IPI and Post-treatment PET Results in Patients With Newly Diagnosed Nodal PTCL

Chonbuk National University Hospital1 个研究点 分布在 1 个国家目标入组 405 人开始时间: 2017年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
405
试验地点
1
主要终点
progression-free survival

研究概览

简要总结

This study is to investigate the prognostic significance of enhanced International Prognostic Index (NCCN-IPI) and post-treatment PET results in patients with newly diagnosed nodal peripheral T-cell lymphoma (PTCL), and establish a risk stratification model for nodal PTCL patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative)
  • Patients diagnosed with between January 1, 2004 and April 30, 2016
  • initially treated with curative intent
  • Patients with standard 18F-fluorodeoxyglucose (FDG) PET or PET-CT data at the time of diagnosis and at the end of primary treatment

排除标准

  • Patients diagnosed with extranodal PTCLs, including followings (extranodal NK/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; EBV-positive T-cell lymphoproliferative childhood disorders, and primary cutaneous lymphomas)
  • Patients with ALCL-ALK+
  • Patients who do not have 18F-FDG PET or PET-CT data either at diagnosis or at the end of treatment available for review

结局指标

主要结局

progression-free survival

时间窗: 5 year

Time between the date of diagnosis and any kinds of death or disease relapse/progrression

次要结局

  • overall survival(5 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ho-Young Yhim

Assistant professor

Chonbuk National University Hospital

研究点 (1)

Loading locations...

相似试验